FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899291216> ?p ?o ?g. }

• W2899291216 endingPage "719" @default.
• W2899291216 startingPage "712" @default.
• W2899291216 abstract "Effective therapies for treating patients with steroid-refractory acute graft-versus-host-disease (SR-aGVHD), particularly strategies that reduce the duration of immunosuppression following remission, are urgently needed. The investigated immunotoxin combination consists of a mixture of anti-CD3 and anti-CD7 antibodies separately conjugated to recombinant ricin A (CD3/CD7-IT), which induces in vivo depletion of T cells and natural killer (NK) cells and suppresses T cell receptor activation. We conducted a phase I/II trial to examine the safety and efficacy of CD3/CD7-IT in 20 patients with SR-aGVHD; 17 of these patients (85%) had severe SR-aGVHD, and all 20 patients had visceral organ involvement, including 18 (90%) with gastrointestinal (GI) involvement and 5 (25%) with liver involvement. A validated 2-biomarker algorithm classified the majority of patients (11 of 20) as high risk. On day 28 after the start of CD3/CD7-IT therapy, the overall response rate was 60% (12 of 20), with 10 patients (50%) achieving a complete response. The 6-month overall survival rate was 60% (12 of 20), including 64% (7 of 11) classified as high risk by biomarkers. The 1-week course of treatment with CD3/CD7-IT caused profound but transient depletion of T cells and NK cells, followed by rapid recovery of the immune system with a diverse TCR Vβ repertoire, and preservation of Epstein-Barr virus- and cytomegalovirus-specific T cell clones. Furthermore, our results indicate that CD3/CD7-IT appeared to be safe and well tolerated, with a relatively low prevalence of manageable and reversible adverse events, primarily worsening of hypoalbuminemia, microangiopathy, and thrombocytopenia. These encouraging results suggest that CD3/CD7-IT may improve patient outcomes in patients with SR-aGVHD." @default.
• W2899291216 created "2018-11-09" @default.
• W2899291216 creator A5006288618 @default.
• W2899291216 creator A5007551307 @default.
• W2899291216 creator A5009079290 @default.
• W2899291216 creator A5012388948 @default.
• W2899291216 creator A5023099227 @default.
• W2899291216 creator A5023300319 @default.
• W2899291216 creator A5027955775 @default.
• W2899291216 creator A5029696219 @default.
• W2899291216 creator A5037371687 @default.
• W2899291216 creator A5042394681 @default.
• W2899291216 creator A5043877705 @default.
• W2899291216 creator A5044267199 @default.
• W2899291216 creator A5047818086 @default.
• W2899291216 creator A5048553030 @default.
• W2899291216 creator A5054248930 @default.
• W2899291216 creator A5071052208 @default.
• W2899291216 creator A5080302229 @default.
• W2899291216 creator A5086841102 @default.
• W2899291216 creator A5091608460 @default.
• W2899291216 date "2019-04-01" @default.
• W2899291216 modified "2023-10-06" @default.
• W2899291216 title "Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease" @default.
• W2899291216 cites W1527416627 @default.
• W2899291216 cites W1676794103 @default.
• W2899291216 cites W1689714760 @default.
• W2899291216 cites W1926479383 @default.
• W2899291216 cites W1965052809 @default.
• W2899291216 cites W1980032822 @default.
• W2899291216 cites W1986916454 @default.
• W2899291216 cites W1993168911 @default.
• W2899291216 cites W1999834650 @default.
• W2899291216 cites W2001947362 @default.
• W2899291216 cites W2004794391 @default.
• W2899291216 cites W2004916618 @default.
• W2899291216 cites W2005426493 @default.
• W2899291216 cites W2005900464 @default.
• W2899291216 cites W2010305809 @default.
• W2899291216 cites W2017467835 @default.
• W2899291216 cites W2039359386 @default.
• W2899291216 cites W2039792011 @default.
• W2899291216 cites W2049774501 @default.
• W2899291216 cites W2053172534 @default.
• W2899291216 cites W2056328782 @default.
• W2899291216 cites W206283783 @default.
• W2899291216 cites W2067258739 @default.
• W2899291216 cites W2082708772 @default.
• W2899291216 cites W2096021498 @default.
• W2899291216 cites W2107611068 @default.
• W2899291216 cites W2123368042 @default.
• W2899291216 cites W2131682431 @default.
• W2899291216 cites W2131840040 @default.
• W2899291216 cites W2139284253 @default.
• W2899291216 cites W2143258371 @default.
• W2899291216 cites W2149590343 @default.
• W2899291216 cites W2153187872 @default.
• W2899291216 cites W2166734004 @default.
• W2899291216 cites W2170458526 @default.
• W2899291216 cites W2180048932 @default.
• W2899291216 cites W2206276344 @default.
• W2899291216 cites W2247915865 @default.
• W2899291216 cites W2321365245 @default.
• W2899291216 cites W2405999620 @default.
• W2899291216 cites W2465355173 @default.
• W2899291216 cites W2472170717 @default.
• W2899291216 cites W2511059306 @default.
• W2899291216 cites W2524753328 @default.
• W2899291216 cites W2556452623 @default.
• W2899291216 cites W2558050630 @default.
• W2899291216 cites W2605177850 @default.
• W2899291216 cites W2611579691 @default.
• W2899291216 cites W2615518215 @default.
• W2899291216 cites W2756071038 @default.
• W2899291216 cites W2767394258 @default.
• W2899291216 cites W2769990542 @default.
• W2899291216 cites W2792985650 @default.
• W2899291216 cites W4241026060 @default.
• W2899291216 cites W4296296481 @default.
• W2899291216 doi "https://doi.org/10.1016/j.bbmt.2018.10.020" @default.
• W2899291216 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6595479" @default.
• W2899291216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30399420" @default.
• W2899291216 hasPublicationYear "2019" @default.
• W2899291216 type Work @default.
• W2899291216 sameAs 2899291216 @default.
• W2899291216 citedByCount "26" @default.
• W2899291216 countsByYear W28992912162019 @default.
• W2899291216 countsByYear W28992912162020 @default.
• W2899291216 countsByYear W28992912162021 @default.
• W2899291216 countsByYear W28992912162022 @default.
• W2899291216 countsByYear W28992912162023 @default.
• W2899291216 crossrefType "journal-article" @default.
• W2899291216 hasAuthorship W2899291216A5006288618 @default.
• W2899291216 hasAuthorship W2899291216A5007551307 @default.
• W2899291216 hasAuthorship W2899291216A5009079290 @default.
• W2899291216 hasAuthorship W2899291216A5012388948 @default.
• W2899291216 hasAuthorship W2899291216A5023099227 @default.
• W2899291216 hasAuthorship W2899291216A5023300319 @default.

• next